A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer.

Br J Cancer · 2021 · PMC7884704 · PMID 33191408

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

did not reach statistical significancep = 0.09so close (0.05 < p ≤ 0.1)

21%, 95% confidence interval [CI] −0.0195 to 0.2651), but the between-group difference did not reach statistical significance (Chi-square test , p = 0.09).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.